Virus-induced autoimmune disease

MG von Herrath, MBA Oldstone - Current opinion in immunology, 1996 - Elsevier
MG von Herrath, MBA Oldstone
Current opinion in immunology, 1996Elsevier
The braking of tolerance or unresponsiveness to self-antigens, involving the activation of
autoreactive lymphocytes, is a critical event leading to autoimmune diseases. The precise
mechanisms by which this can occur are mostly unknown. Viruses have been implicated in
this process, among other etiological factors, such as genetic predisposition and cytokine
activity. Several ways have been proposed by which a viral infection might break tolerance
to self and trigger an autoreactive cascade that ultimately leads to the destruction of a …
The braking of tolerance or unresponsiveness to self-antigens, involving the activation of autoreactive lymphocytes, is a critical event leading to autoimmune diseases. The precise mechanisms by which this can occur are mostly unknown. Viruses have been implicated in this process, among other etiological factors, such as genetic predisposition and cytokine activity. Several ways have been proposed by which a viral infection might break tolerance to self and trigger an autoreactive cascade that ultimately leads to the destruction of a specific cell type or an entire organ. The process termed ‘molecular mimicry’ and the use of transgenic models in which viral and host genes can be manipulated to analyze their effects in causing autoimmunity have been particular focuses for research. For example, there is a transgenic murine model of virus-induced autoimmune disease, in which a known viral gene is selectively expressed as a self-antigen in β cells of the pancreas. In these mice, insulin-dependent diabetes develops after either a viral infection, the release of a cytokine such as IFN-γ, or the expression of the costimulatory molecule B7.1 in the islets of Langerhans. Recent studies using this model have contributed to the understanding of the pathogenesis of virus-induced autoimmune disease and have furthered the design and testing of novel immunotherapeutic approaches.
Elsevier